1878 related articles for article (PubMed ID: 31844003)
1. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.
Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003
[TBL] [Abstract][Full Text] [Related]
2. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria.
Doymaz MZ; Karaaslan E
Infect Dis (Lond); 2019 Sep; 51(9):676-682. PubMed ID: 31298061
[No Abstract] [Full Text] [Related]
3. Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii.
Tsuji BT; Landersdorfer CB; Lenhard JR; Cheah SE; Thamlikitkul V; Rao GG; Holden PN; Forrest A; Bulitta JB; Nation RL; Li J
Antimicrob Agents Chemother; 2016 Jul; 60(7):3913-20. PubMed ID: 27067330
[TBL] [Abstract][Full Text] [Related]
4. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.
Hussein MH; Schneider EK; Elliott AG; Han M; Reyes-Ortega F; Morris F; Blastovich MAT; Jasim R; Currie B; Mayo M; Baker M; Cooper MA; Li J; Velkov T
Microb Drug Resist; 2017 Jul; 23(5):640-650. PubMed ID: 27935770
[TBL] [Abstract][Full Text] [Related]
5. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
Dowzicky MJ; Park CH
Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
[TBL] [Abstract][Full Text] [Related]
7. Structural Modification of Lipopolysaccharide Conferred by
Liu YY; Chandler CE; Leung LM; McElheny CL; Mettus RT; Shanks RMQ; Liu JH; Goodlett DR; Ernst RK; Doi Y
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373195
[No Abstract] [Full Text] [Related]
8. Resistance to polymyxins in Gram-negative organisms.
Jeannot K; Bolard A; Plésiat P
Int J Antimicrob Agents; 2017 May; 49(5):526-535. PubMed ID: 28163137
[TBL] [Abstract][Full Text] [Related]
9.
Chen H; Li H; Liu Z; Li J
Microb Drug Resist; 2020 Sep; 26(9):1108-1119. PubMed ID: 32349617
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of distribution and drug resistance of pathogens from the wounds of 1 310 thermal burn patients].
Zhang C; Gong YL; Luo XQ; Liu MX; Peng YZ
Zhonghua Shao Shang Za Zhi; 2018 Nov; 34(11):802-808. PubMed ID: 30481922
[No Abstract] [Full Text] [Related]
11. Synergistic combinations of polymyxins.
Lenhard JR; Nation RL; Tsuji BT
Int J Antimicrob Agents; 2016 Dec; 48(6):607-613. PubMed ID: 27865626
[TBL] [Abstract][Full Text] [Related]
12. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
Ardebili A; Izanloo A; Rastegar M
Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
[TBL] [Abstract][Full Text] [Related]
13. Polymyxin Combinations Combat
Bulman ZP; Chen L; Walsh TJ; Satlin MJ; Qian Y; Bulitta JB; Peloquin CA; Holden PN; Nation RL; Li J; Kreiswirth BN; Tsuji BT
mBio; 2017 Jul; 8(4):. PubMed ID: 28743810
[TBL] [Abstract][Full Text] [Related]
14. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
[TBL] [Abstract][Full Text] [Related]
15.
Duncan LR; Wang W; Sader HS
Antimicrob Agents Chemother; 2022 May; 66(5):e0013922. PubMed ID: 35475635
[TBL] [Abstract][Full Text] [Related]
16. Functional Differences between E. coli and ESKAPE Pathogen GroES/GroEL.
Sivinski J; Ambrose AJ; Panfilenko I; Zerio CJ; Machulis JM; Mollasalehi N; Kaneko LK; Stevens M; Ray AM; Park Y; Wu C; Hoang QQ; Johnson SM; Chapman E
mBio; 2021 Jan; 12(1):. PubMed ID: 33436430
[TBL] [Abstract][Full Text] [Related]
17. Performances of the Rapid Polymyxin
Lescat M; Poirel L; Jayol A; Nordmann P
Microb Drug Resist; 2019 May; 25(4):520-523. PubMed ID: 30508392
[No Abstract] [Full Text] [Related]
18. Inhibition of the ATP Synthase Eliminates the Intrinsic Resistance of
Vestergaard M; Nøhr-Meldgaard K; Bojer MS; Krogsgård Nielsen C; Meyer RL; Slavetinsky C; Peschel A; Ingmer H
mBio; 2017 Sep; 8(5):. PubMed ID: 28874470
[No Abstract] [Full Text] [Related]
19. Rediscovering the octapeptins.
Velkov T; Roberts KD; Li J
Nat Prod Rep; 2017 Mar; 34(3):295-309. PubMed ID: 28180225
[TBL] [Abstract][Full Text] [Related]
20. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City.
Quale J; Shah N; Kelly P; Babu E; Backer M; Rosas-Garcia G; Salamera J; George A; Bratu S; Landman D
Microb Drug Resist; 2012 Apr; 18(2):132-6. PubMed ID: 22196342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
